Since 2017, the U.S. Food and Drug Administration (FDA) has approved six chimeric antigen receptor (CAR) T cell therapies for the treatment of blood cancers (1). Underlying the excitement about these therapies are concerns about patients’ transient responses to CAR T-cell infusions, limiting their chances of long-term survival. CAR T cells are even less effective against solid tumors because immunosuppressive factors in the tumor microenvironment (TME) suppress T cell activity, thereby promoting tumor development and evading treatment.
Scientists work hard to find immunosuppressive genes that contribute to T cell dysfunction in the TME, such as using CRISPR knockout genes for loss-of-function screening.In a recently published study natureResearchers at the New York Genome Center and New York University took a different approach and proposed the possibility of CAR T cells that enhance tumor killing by targeting positive regulators that enhance T cell function (2).
Geneticist Neville Sanjana and his team at the New York Genome Center screened nearly 12,000 genes to find genes that could boost T cells’ anti-tumor activity. The researchers constructed a lentiviral library containing a collection of protein-coding genes from the human genome and transduced the library into T cells. They monitored the proliferation of these T cells and captured many highly expressed genes involved in multiple immune processes, such as lymphocyte proliferation and interferon production. To the team’s surprise, the top-ranked gene was lymphotoxin-beta receptor (LTBR).
LTBR is a tumor necrosis factor receptor that mediates cytokine release and apoptosis and helps regulate lymphoid organogenesis and inflammation. Although T and B cells often express LTBR ligands, the receptor itself is usually not present in these cells (3).
To understand how exogenous LTBR affects T cell function, Sanjana and her team used single-cell sequencing to analyze the T cell transcriptome. They found that LTBR triggered the upregulation of multiple genes and enhanced multiple immune responses, including promoting cytokine secretion, promoting T cell proliferation, and reducing apoptosis.
Based on sequencing data, the authors identified nuclear factor (NF)-κB, a key immune response regulator, as the most significantly upregulated gene in LTBR-transduced T cells. NF-κB typically coordinates various transcription factors in different pathways to trigger inflammatory responses and promote immune cell development (4). In LTBR-transduced T cells, researchers demonstrated that NF-κB also upregulated several key inflammatory pathways and transcription factors, such as NF-κB p65 and p52. These data helped Sanjana and her team determine which signaling pathways LTBR acts on to stimulate T cell immune activity.
The team then co-expressed LTBRs with FDA-approved CARs and tested their antigen-specific responses and cytotoxicity in patient T cells. They found that compared with original CAR T cells, LTBR CAR T cells exhibited increased cytokine secretion and cytotoxicity against tumor cells. These results highlight the potential of using immune-enhancing genetically engineered T cells as a way to improve CAR T immunotherapy, particularly for solid cancers.
Publishers Mindscape Developers P.F. Magic Release date 1998 Genre Simulation Game rating Description of the…
Editors Activision, Inc. Developers superego games Release date 2006 Gender Adventure Game Rating Game Description…
Editors Terraglyph Interactive Studios, Warner Bros. Interactive Entertainment. Developers Terraglifo interactive studios Release date nineteen…
Editors Sega, Digital Images, Screaming Villains, Limited Run Games Developers Digital Images, Inc. Release date…
Editors Davilex Games BV Developers Davilex Games BV Release date 1998 Gender Careers Game Rating…
Editors Sony Computer Entertainment, Disney Interactive Studios Developers High voltage software Release date 2002 Gender…